DK3172221T3 - Oprensningsplatform til bispecifikke antistoffer - Google Patents

Oprensningsplatform til bispecifikke antistoffer Download PDF

Info

Publication number
DK3172221T3
DK3172221T3 DK15750182.6T DK15750182T DK3172221T3 DK 3172221 T3 DK3172221 T3 DK 3172221T3 DK 15750182 T DK15750182 T DK 15750182T DK 3172221 T3 DK3172221 T3 DK 3172221T3
Authority
DK
Denmark
Prior art keywords
bispecific antibodies
purification platform
purification
platform
bispecific
Prior art date
Application number
DK15750182.6T
Other languages
English (en)
Inventor
Andrew Tustian
Benjamin Adams
John Mattila
Hanne Bak
Christine Endicott
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3172221T3 publication Critical patent/DK3172221T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15750182.6T 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer DK3172221T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029463P 2014-07-26 2014-07-26
PCT/US2015/041936 WO2016018740A2 (en) 2014-07-26 2015-07-24 Purification platform for bispecific antibodies

Publications (1)

Publication Number Publication Date
DK3172221T3 true DK3172221T3 (da) 2021-08-09

Family

ID=53836215

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15750182.6T DK3172221T3 (da) 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer
DK21170436.6T DK3912987T3 (da) 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21170436.6T DK3912987T3 (da) 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer

Country Status (20)

Country Link
US (1) US10626142B2 (da)
EP (2) EP3172221B1 (da)
JP (1) JP6702967B2 (da)
KR (1) KR102440737B1 (da)
CN (1) CN107074906B (da)
AR (1) AR101262A1 (da)
AU (1) AU2015298156B2 (da)
CA (1) CA2955618A1 (da)
DK (2) DK3172221T3 (da)
EA (1) EA036154B1 (da)
ES (2) ES2942533T3 (da)
FI (1) FI3912987T3 (da)
IL (1) IL255198B (da)
MX (1) MX2017001217A (da)
MY (1) MY187051A (da)
PL (2) PL3172221T3 (da)
SG (2) SG11201700157VA (da)
TW (1) TWI704155B (da)
WO (1) WO2016018740A2 (da)
ZA (1) ZA201700622B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP3789400A1 (en) 2007-09-26 2021-03-10 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
EP4279511A3 (en) 2010-11-30 2024-01-24 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3549606A1 (en) * 2015-05-28 2019-10-09 Bio-rad Laboratories, Inc. Affinity ligands and methods relating thereto
AU2016381992B2 (en) * 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
KR20230113662A (ko) * 2016-06-17 2023-07-31 제넨테크, 인크. 다중 특이적 항체의 정제
KR101933656B1 (ko) 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
US11155575B2 (en) 2018-03-21 2021-10-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbent, devices and methods
GB201805142D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Bioprocess R&D Ab Separation method
CN112771379B (zh) * 2018-08-17 2024-07-02 瑞泽恩制药公司 用于测定多聚体蛋白质的量和纯度的方法和色谱系统
JPWO2020066270A1 (ja) * 2018-09-28 2021-08-30 株式会社カネカ κ鎖可変領域を含む抗体および／または抗体断片の製造方法
SG11202103628PA (en) 2018-10-31 2021-05-28 Regeneron Pharma Method and system of identifying and quantifying a protein
AU2019384790A1 (en) 2018-11-21 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
CN112996801A (zh) * 2018-11-26 2021-06-18 北卡罗来纳州大学 用于捕获宿主细胞蛋白的肽配体
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
CA3124770A1 (en) 2018-12-24 2020-07-02 Sanofi Pseudofab-based multispecific binding proteins
US11655286B2 (en) 2019-06-11 2023-05-23 Regeneron Pharmaceuticals, Inc. Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
JP2022536470A (ja) * 2019-06-13 2022-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多段階クロマトグラフィープロセス中の望ましくない成分を除去する方法
IL309560A (en) 2019-12-06 2024-02-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
EP4141025A4 (en) * 2019-12-26 2024-04-24 ABL Bio, Inc. METHOD FOR PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES USING PROTEIN A AFFINITY CHROMATOGRAPHY
KR20210084054A (ko) 2019-12-27 2021-07-07 케이에스광학주식회사 투명한 방탄 적층 구조물
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
EP4281467A1 (en) * 2021-01-25 2023-11-29 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
EP4421089A1 (en) * 2021-10-19 2024-08-28 Alteogen, Inc. Method for purifying fusion protein having igg fc domain
WO2023247468A2 (en) * 2022-06-22 2023-12-28 Puridify Limited Kappa light chain-binding convection matrix
WO2024123698A1 (en) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
EP0826695B1 (de) 1996-09-03 2001-12-12 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
WO2000018435A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20030224000A1 (en) 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
ATE514717T1 (de) 2002-07-18 2011-07-15 Merus B V Rekombinante produktion von antikörpermischungen
EP2388274A1 (en) * 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
SG149759A1 (en) * 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
WO2010030222A1 (en) * 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PT2975051T (pt) 2009-06-26 2021-05-04 Regeneron Pharma Anticorpos biespecíficos rapidamente isolados com formato de imunoglobulina nativa
KR101856792B1 (ko) * 2009-12-25 2018-05-11 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
EP4279511A3 (en) * 2010-11-30 2024-01-24 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP2500073A1 (en) * 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
CA2867020C (en) 2012-03-13 2022-11-15 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
AU2013322710A1 (en) * 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Also Published As

Publication number Publication date
EA036154B1 (ru) 2020-10-06
FI3912987T3 (fi) 2023-06-19
TW201617359A (zh) 2016-05-16
WO2016018740A3 (en) 2016-03-17
TWI704155B (zh) 2020-09-11
BR112017001443A2 (pt) 2017-12-05
IL255198B (en) 2022-04-01
NZ728700A (en) 2023-09-29
AU2015298156A1 (en) 2017-02-23
IL255198A0 (en) 2017-12-31
MX2017001217A (es) 2017-05-03
PL3912987T3 (pl) 2023-07-24
JP6702967B2 (ja) 2020-06-03
SG10201900661YA (en) 2019-02-27
DK3912987T3 (da) 2023-05-01
EP3172221B1 (en) 2021-07-07
KR102440737B1 (ko) 2022-09-06
ZA201700622B (en) 2020-05-27
ES2942533T3 (es) 2023-06-02
PL3172221T3 (pl) 2021-12-27
SG11201700157VA (en) 2017-02-27
EA201790247A1 (ru) 2017-08-31
CN107074906B (zh) 2021-05-14
EP3912987B9 (en) 2023-05-31
CA2955618A1 (en) 2016-02-04
US20160024147A1 (en) 2016-01-28
EP3172221A2 (en) 2017-05-31
CN107074906A (zh) 2017-08-18
AR101262A1 (es) 2016-12-07
EP3912987B1 (en) 2023-03-22
ES2881026T3 (es) 2021-11-26
MY187051A (en) 2021-08-27
JP2017524740A (ja) 2017-08-31
US10626142B2 (en) 2020-04-21
KR20170035941A (ko) 2017-03-31
WO2016018740A2 (en) 2016-02-04
AU2015298156B2 (en) 2020-07-16
WO2016018740A8 (en) 2021-06-10
EP3912987A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
DK3912987T3 (da) Oprensningsplatform til bispecifikke antistoffer
NL301117I2 (nl) trastuzumab deruxtecan
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3608337T3 (da) Bispecifikke T-celleaktiverende antigenbindende molekyler
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3332006T5 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3126395T3 (da) Multispecifikke antistoffer
DK3266792T3 (da) Fremgangsmåde til peptidsyntese
DK3191517T3 (da) Krydsreaktive siglec-antistoffer
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3131928T3 (da) Trifunktionelt antigenbindende molekyle
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
DK3125898T3 (da) Farmakofor til trail-induktion
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3215530T3 (da) Forbedrede il-6 antistoffer
DK3209541T3 (da) Sadel til et køretøj
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3197589T3 (da) Fremgangsmåde til oprensning af væsker
BR112017002234A2 (pt) anticorpos anti-pd-l1
TH1601006445A (th) โครงสร้างสำหรับบรรจุของยานพาหนะ
TH1701000091A (th) วิธีการสำหรับการยึดติดผ้า-อิลาสโตเมอร์
UA29847S (uk) Посудина для закусок
UA29846S (uk) Посудина для закусок